A New Way to Prevent Transplant Complications
Stem cell transplants can offer patients with certain blood cancers a chance at recovery. However, even after a successful transplant, serious complications can develop.
One of these is graft-versus-host disease (GVHD), a condition in which transplanted immune cells mistakenly attack the recipient’s healthy tissues. It can affect the skin, liver, and digestive system, sometimes causing long-term health problems.
A 2025 clinical study published in Journal of Clinical Oncology explored whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) could help prevent these complications before they occur.
Helping the Immune System Find Balance
Mesenchymal stem cells are being investigated for their ability to regulate inflammation and immune responses. For this study, researchers used UC-MSCs derived from donated human umbilical cord tissue. Rather than replacing blood-forming cells, the goal was to influence immune activity and reduce harmful reactions following transplantation.
Researchers wanted to determine whether repeated UC-MSC infusions could provide additional protection alongside standard preventive medications.
Inside the Clinical Trial
The randomized clinical trial involved 192 patients, ages 18–60, across three transplantation centers in China.
All participants received a partially matched family-donor stem cell transplant and were divided into two groups:
- UC-MSC group: 96 patients received standard preventive medications plus eight UC-MSC infusions.
- Control group: 96 patients received standard preventive medications without UC-MSC treatment.
Researchers monitored participants for acute GVHD, chronic GVHD, treatment safety, and other transplant-related outcomes.
Encouraging Results for GVHD Prevention
The findings revealed meaningful differences between the groups.
At two years, severe chronic GVHD occurred in an estimated 5.5% of patients receiving UC-MSCs, compared with 14.8% in the control group. Overall chronic GVHD rates were also lower, affecting 27.6% of UC-MSC recipients compared with 45.5% of patients receiving standard prevention alone.
The difference was particularly noticeable for acute GVHD, with estimated rates of:
- 17.7% in the UC-MSC group.
- 47.9% in the control group.
These results suggest that UC-MSC therapy may help reduce harmful immune reactions following transplantation.
More Patients Avoided Major Complications
Researchers also measured GVHD-free and relapse-free survival, which evaluates whether patients remain alive without major GVHD complications or leukemia relapse.
At three years, the estimated rate was 62.4% among UC-MSC recipients, compared with 32.0% in the control group.
Importantly, researchers did not observe a statistically significant increase in leukemia relapse or non-relapse mortality among patients receiving UC-MSCs. Overall survival was not significantly different between the groups.
What About Safety?
The safety findings were encouraging, and researchers reported no infusion-related allergic reactions, infections, pain, vein inflammation, or electrolyte disturbances during the monitored treatment period. These findings suggest that repeated UC-MSC infusions were generally well tolerated in this study.
A Promising Direction for Regenerative Medicine
One of the most interesting aspects of this research is its preventive approach. Rather than treating GVHD after symptoms appear, researchers investigated whether UC-MSCs could help regulate immune activity during the early stages of recovery.
Although the results were promising, the study was open-label, meaning participants and researchers knew which treatments were administered. Additional trials are needed to confirm effectiveness and establish optimal treatment schedules.
Nevertheless, this research highlights the potential of umbilical cord-derived mesenchymal stem cells to help make certain stem cell transplants safer and improve patients’ recovery experiences.
Source
Yao H, Huang R, Fu H, et al. Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial. Journal of Clinical Oncology. 2025;43(17):1997–2006. DOI: 10.1200/JCO-24-02119
Full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12169861/
Related Treatment Pages